Stephens & Co. analyst Chris Cooley maintains SmileDirectClub (NASDAQ:SDC) with a Equal-Weight and lowers the price target from $5 to $3.
Amgen To Report At ASCO Jun. 4-6
Results From the PARADIGM Phase 3 Head-to-Head Trial of Vectibix® (panitumumab) Versus Bevacizumab in Untreated RAS Wild-Type Metastatic Colorectal Cancer*
Largest Evaluation of Acquired Resistance to